Celcuity, Inc. (CELC)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$95.70-0.76%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CELC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -42.4% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CELC — earnings miss
Dated 2026-08-13
Results of Operations and Financial Condition. On August 13, 2026, Celcuity Inc. (the “Company”) issued a press release regarding the Company’s financial results for the quarter ended June 30, 2026. A copy of the Company’s press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02, including the accompanying exhibit, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange…
Why it matters: A good subcutaneous formulation could improve treatment choices and help patients stick to their plans.
Supportive ifThe company reports good results from the injection trials.
Worry ifThe injection form is having major delays or issues.
Why it matters: A buyback could show that management believes in the company's value.
Supportive ifDetails about the share buyback program and when it will happen are announced.
Worry ifNo new announcements or delays in the buyback process.
Why it matters: The FDA's choice will affect Celcuity's plans for REVTORPYK.
Supportive ifFDA grants approval for REVTORPYK by the PDUFA date.
Worry ifFDA denies approval or asks for more data.
Why it matters: Submitting the sNDA could increase the use of gedatolisib. This would boost its market potential.
Supportive ifCelcuity submits the sNDA to the FDA in Q3 2026.
Worry ifThe sNDA submission is delayed or not made as planned.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$231 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $628 loss on $10,000 · 6.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,325 loss on $10,000 · 43.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: How the company handles debt affects its financial health. It also impacts growth plans.
Worry ifThe company shares a clear plan for managing new debt. It expects positive cash flow.
Less concerning ifNo clear strategy is provided, or debt levels increase without a plan.
Why it matters: Approval lets Celcuity launch gedatolisib. This helps treat breast cancer.
Supportive ifFDA approval confirms gedatolisib's use for HR+/HER2- breast cancer.
Worry ifNo approval announcement or a delay in the FDA decision.
Why it matters: Results will show how well gedatolisib works as a first treatment for breast cancer.
Watch forPositive results show better treatment effects in patients with HR+/HER2- breast cancer.
Also watch forNegative results show no real gains over current treatments.
Why it matters: Good capital management is important. It helps fund operations and keeps the company stable.
Worry ifManagement announces a successful debt issue that helps cash flow.
Less concerning ifManagement reports problems with debt or cash flow.
Why it matters: The launch of gedatolisib is key for revenue growth. It shows market acceptance.
Supportive ifGedatolisib will launch on time in Q3 2026. Early sales reports are positive.
Worry ifLaunch is delayed or initial sales are disappointing.
Why it matters: Earnings results will show if the company meets expectations. This impacts investor feelings.
Watch forThe earnings report shows a big beat against analyst expectations.
Also watch forThe earnings report shows a big miss against analyst expectations.
Why it matters: Starting shipments shows the company can launch its first FDA-approved drug. This is important for making money.
Supportive ifShipments of REVTORPYK begin as stated in the Q3 2026 timeline.
Worry ifShipments do not start by the end of Q3 2026.
Why it matters: The sNDA is key for expanding the market for gedatolisib. It shows progress in testing.
Supportive ifCelcuity submits the sNDA to the FDA as planned in Q3 2026.
Worry ifThe sNDA submission is delayed beyond Q3 2026.
Why it matters: Updates on the trial will show how well gedatolisib performs in first-line treatment. This could affect future sales.
Watch forCelcuity shares good news from the VIKTORIA-2 trial.
Also watch forCelcuity shares bad news or delays from the VIKTORIA-2 trial.